Live Breaking News & Updates on Managing Director Krishna Ella
Stay updated with breaking news from Managing director krishna ella. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Final results will be out in June It added that safety and efficacy results from the final analysis of Covaxin will be available in June, and the final report will be submitted to a peer-reviewed publication. Based on the achievement of the success criteria, placebo recipients have now become eligible to receive two doses of Covaxin, it said. Phase 3 clinical trials of Covaxin saw participation of 25,800 volunteers between 18-98 years of age. Ten per cent of the total volunteers were aged more than 60. Efficacy against SARS-Cov-2 has been established. Covaxin has demonstrated an excellent safety record in human clinical trials and in usage under emergency use. Covaxin is now a global innovator vaccine derived from R&D in India, Bharat Biotech Chairman and Managing Director Krishna Ella said. ....
Bharat Biotech Says Covaxin Shows 78% Efficacy Against Mild To Severe COVID-19 Bharat Biotech Says Covaxin Shows 78% Efficacy Against Mild To Severe COVID-19 Efficacy against SARS-Cov-2 has been established. Covaxin has demonstrated an excellent safety record in human clinical trials and in usage under emergency use. Covaxin is now a global innovator vaccine derived from R&D in India, Bharat Biotech Chairman and Managing Director Krishna Ella said. Bharat Biotech said Covaxin showed efficacy of 78% against mild, moderate and severe cases New Delhi: Bharat Biotech on Wednesday said its coronavirus vaccine Covaxin has shown efficacy of 78 per cent against mild, moderate and severe cases of COVID-19, as per Phase III interim analysis results. ....
Covaxin Is 78% Effective Against Mild To Severe Covid-19 Infections: Bharat Biotech outlookindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from outlookindia.com Daily Mail and Mail on Sunday newspapers.
Covaxin shows 78% efficacy against mild, moderate severe Covid cases Bharat Biotech vaccine 70 per cent efficient in asymptomatic patients according to interim analysis results Bharat Biotech on Wednesday said its coronavirus vaccine Covaxin has shown efficacy of 78 per cent against mild, moderate and severe cases of Covid-19, as per Phase III interim analysis results. The vaccine maker noted that the second interim data of the Phase III study also showed that chances of hospitalisation due to the infectious disease were reduced by 100 per cent after taking the Covaxin jab. “Due to the recent surge in cases, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78 per cent against mild, moderate, and severe Covid-19 disease,” Bharat Biotech said in a statement. ....
‘5 decades of vaccine excellence is paying off’ March 06, 2021 Suchitra Ella, Joint Managing Director of Bharat Biotech× Bharat Bio’s Suchitra Ella says India will play a key role supplying Covid vaccines to the world
The near-five decades of vaccine manufacturing capability and excellence is paying off with Hyderabad set to play a significant role in the global supply chain of Covid-19 antidotes, said Suchitra Ella, Joint Managing Director of Bharat Biotech, which makes Covaxin. Speaking at a CII conference on ‘Industry Reset: Summit on strategic manufacturing in digital era’, the Bharat Biotech co-founder said, “What started as an initiative driven by government institutions 4-5 decades ago, with significant participation of Indian research institutions for basic vaccines has now grown to become a big industry with India accounting for 60-65 per cent of global supplies of vaccines and Hyderabad accounting for about 70 per cent of India’s ....